Genetics and emerging treatments for Duchenne and Becker muscular dystrophy

Pediatr Clin North Am. 2015 Jun;62(3):723-42. doi: 10.1016/j.pcl.2015.03.008. Epub 2015 Apr 20.

Abstract

Mutations in the DMD gene result in Duchenne or Becker muscular dystrophy due to absent or altered expression of the dystrophin protein. The more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of other presenting signs, such as delayed motor or cognitive milestones, or elevated serum transaminases. Becker muscular dystrophy is milder, often presenting after age 5, with ambulation frequently preserved past 20 years and sometimes into late decades.

Keywords: Becker; DMD gene; Duchenne; Dystrophin; Exon skipping; Gene therapy; Muscular dystrophy; Nonsense suppression.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review
  • Video-Audio Media

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Child, Preschool
  • Dystrophin / genetics
  • Humans
  • Infant
  • Male
  • Muscular Dystrophy, Duchenne / diagnosis
  • Muscular Dystrophy, Duchenne / drug therapy*
  • Muscular Dystrophy, Duchenne / genetics*
  • Mutation / genetics

Substances

  • Adrenal Cortex Hormones
  • Dystrophin